title: Improving the efficacy of conventional therapy by adding andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease: a randomized controlled trial.
abstract: Background. Herb-derived compound andrographolide sulfonate (called Xiyanping injection) recommended control measure for severe hand, foot, and mouth disease (HFMD) by the Ministry of Health (China) during the 2010 epidemic. However, there is a lack of good quality evidence directly comparing the efficacy of Andrographolide Sulfonate combination therapy with conventional therapy. Methods. 230 patients were randomly assigned to 7-10 days of Andrographolide Sulfonate 5-10 mg/Kg/day and conventional therapy, or conventional therapy alone. Results. The major complications occurred less often after Andrographolide Sulfonate (2.6% versus 12.1%; risk difference [RD], 0.94; 95% CI, 0.28-1.61; P = 0.006). Median fever clearance times were 96 hours (CI, 80 to 126) for conventional therapy recipients and 48 hours (CI, 36 to 54) for Andrographolide Sulfonate combination-treated patients (χ(2) = 16.57, P < 0.001). The two groups did not differ in terms of HFMD-cause mortality (P = 1.00) and duration of hospitalization (P = 0.70). There was one death in conventional therapy group. No important adverse event was found in Andrographolide Sulfonate combination therapy group. Conclusions. The addition of Andrographolide Sulfonate to conventional therapy reduced the occurrence of major complications, fever clearance time, and the healing time of typical skin or oral mucosa lesions in children with severe HFMD.
authors: You'an Hospital, Capital Medical University, Beijing, Fengtai 100069, China.
authors: Xiuhui
authors: X
authors: Li
authors: Chi
authors: C
authors: Zhang
authors: Qingsheng
authors: Q
authors: Shi
authors: Tong
authors: T
authors: Yang
authors: Qingxiong
authors: Q
authors: Zhu
authors: Yimei
authors: Y
authors: Tian
authors: Cheng
authors: C
authors: Lu
authors: Zhiying
authors: Z
authors: Zhang
authors: Zhongsheng
authors: Z
authors: Jiang
authors: Hongying
authors: H
authors: Zhou
authors: Xiaofeng
authors: X
authors: Wen
authors: Huasheng
authors: H
authors: Yang
authors: Xiaorong
authors: X
authors: Ding
authors: Lanchun
authors: L
authors: Liang
authors: Yan
authors: Y
authors: Liu
authors: Yongyan
authors: Y
authors: Wang
authors: Aiping
authors: A
authors: Lu
references: Int J Health Geogr. 2011 Apr 05;10:25
references: 21466689
references: Drug Deliv. 2000 Oct-Dec;7(4):209-13
references: 11195427
references: N Engl J Med. 1999 Sep 23;341(13):929-35
references: 10498487
references: Br J Pharmacol. 2002 Jan;135(2):399-406
references: 11815375
references: Emerg Infect Dis. 2007 Nov;13(11):1733-41
references: 18217559
references: Acta Paediatr. 2003 Oct;92(10):1163-9
references: 14632332
references: J Clin Virol. 2012 Apr;53(4):285-9
references: 22265829
references: BMC Infect Dis. 2009 Jan 19;9:3
references: 19152683
references: Korean J Pediatr. 2011 Jan;54(1):11-6
references: 21359055
references: Clin Infect Dis. 2007 Mar 1;44(5):646-56
references: 17278054
references: Phytother Res. 2000 Aug;14(5):333-8
references: 10925397
references: N Engl J Med. 1999 Sep 23;341(13):936-42
references: 10498488